hypertensive patients with chronic kidney disease
Conditions
Interventions
Group 1: administer the Aliskiren add on ARB Duration of study: 2011.9.1 to 2012.12.31 Duration of registration: 6 months Obsevation period: 24 weeks after the administration
Group 2: increase the
Sponsors
Department of Internal Medicine, Division of Nephrology, Juntendo University Faculty of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. patients with proteinuria (more than 0.3g/g Cr) 2. In cases that systolic BP is over 130mmHg and diastolic BP is over 80mmHg who administer standard dose of ARB. The standard dose of ARB are as below. Valsartan 80mg, Losartan 50mg, Candesartan 8mg, Terumisartan 40mg, Olmesartan 20mg
Exclusion criteria
Exclusion criteria: 1. systolic BP is over 180mmHg, or diastolic BP is over 110mmHg 2. Severe diabetic patients whose HbA1c is over 8.5% 3. In case of severe hepatic injuries 4. nephrotic syndrome 5. the patients with pregnant or possibly pregnant 6. in case with contraindication of Aliskiren
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Levels of urinary protein after 12 and 24 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Plasma aldosterone Urinary sodium Blood pressure Estimation glomerulus filtration (eGFR) Serum potassium, serum creatinine Plasma renin activity Serum thrombomodulin Serum cystatin C Fibrinolysis system marker (plasma PAI-I) Oxidative stress marker (urinary 8-OHDG) Harmful phenomenon will be analyzed after 12 and 24 wekks | — |
Countries
Japan
Contacts
Public ContactHitoshi Suzuki
Juntendo University Faculty of Medicine Department of Internal Medicine, Division of Nephrology
Outcome results
None listed